Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5804389 | 0.94 | MCHR1 (0.45) | ROCK2MCHR1ROCK1 | |
| SCHEMBL5846949 | 0.87 | PDE10A (0.39) | ROCK2MCHR1HDAC8HDAC6 | |
| SCHEMBL5760136 | 0.86 | ROCK2 (0.51) | LMNAMAPTROCK2MCHR1HDAC8 | |
| SCHEMBL5762721 | 0.86 | MCHR1 (0.48) | ROCK2MCHR1ROCK1 | |
| SCHEMBL5846345 | 0.86 | EGLN1 (0.39) | MAPTEGLN1ROCK2MCHR1HDAC8 | |
| SCHEMBL5762922 | 0.84 | MCHR1 (0.47) | ROCK2MCHR1CHIA | |
| SCHEMBL5759920 | 0.84 | TRPV1 (0.42) | ROCK2MCHR1CHIA | |
| SCHEMBL5761129 | 0.83 | MCHR1 (0.45) | MCHR1 | |
| SCHEMBL5763103 | 0.83 | HPGD (0.43) | MAPTROCK2CHIA | |
| SCHEMBL5790448 | 0.83 | ROCK2 (0.37) | LMNAMAPTROCK2MCHR1CHIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101885-B2 | 1-(4-Bromo-phenyl)-3-[2-(4-methyl-piperazin-1-yl)-pyridin-3-yloxy]-pyrrolidin-2-one; antagonists of the serotonin 5HT1B receptor; treating depression | PFIZER INC (US) | 2006-09-05 | — | — | US | claimed |
| EP-1638932-A1 | NOVEL PIPERAZINYL-ARYLOXY AND PIPERAZINYL-HETEROARYLOXY-N-ARYL LACTAMS | Pfizer Products Inc. (US) | 2006-03-29 | — | — | EP | claimed |
| US-20040266781-A1 | Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams | PFIZER INC | 2004-12-30 | — | — | US | claimed |
| WO-2004110994-A1 | NOVEL PIPERAZINYL-ARYLOXY AND PIPERAZINYL-HETEROARYLOXY-N-ARYL LACTAMS | PFIZER PRODUCTS INC. (US) | 2004-12-23 | — | — | WO | claimed |
| US-7101885-B2 | 1-(4-Bromo-phenyl)-3-[2-(4-methyl-piperazin-1-yl)-pyridin-3-yloxy]-pyrrolidin-2-one; antagonists of the serotonin 5HT1B receptor; treating depression | PFIZER INC (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040266781-A1 | Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams | PFIZER INC | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266781-A1 | Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams | OPRD1, HTR5A, PTGDR | LMNA 417/4885MAPT 2883/4885EGLN1 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.